$WVE
Wave Life Sciences Ltd.

2021 Q1 Form 10-K Financial Statement

#000156459021010718 Filed on March 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $20.08M $2.400M
YoY Change -100.0% 25.64% -33.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.08M $42.51M $13.81M
YoY Change -22.46% -13.01% 8.31%
% of Gross Profit
Research & Development $33.39M $130.9M $49.13M
YoY Change -18.87% -25.36% 23.41%
% of Gross Profit
Depreciation & Amortization $1.948M $8.100M $2.010M
YoY Change -4.46% 6.58% 17.54%
% of Gross Profit
Operating Expenses $43.47M $173.5M $62.93M
YoY Change -19.73% -22.67% 19.73%
Operating Profit -$43.47M -$153.4M -$60.53M
YoY Change -13.05% -26.37% 23.68%
Interest Expense $10.00K -$16.00K $740.0K
YoY Change -97.44% -155.17% -26.73%
% of Operating Profit
Other Income/Expense, Net $1.007M $2.058M $3.030M
YoY Change -52.5% -85.98% -69.52%
Pretax Income -$42.46M -$150.8M -$56.77M
YoY Change -10.58% -22.15% 49.43%
Income Tax $0.00 -$841.0K $0.00
% Of Pretax Income
Net Earnings -$42.46M -$149.9M -$56.77M
YoY Change -10.59% -22.58% 49.84%
Net Earnings / Revenue -746.68% -2365.42%
Basic Earnings Per Share
Diluted Earnings Per Share -$864.8K -$3.821M -$1.655M
COMMON SHARES
Basic Shares Outstanding 49.00M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.5M $184.5M $147.2M
YoY Change 22.83% 25.34% -15.79%
Cash & Equivalents $148.5M $184.5M $147.2M
Short-Term Investments
Other Short-Term Assets $16.00M $15.50M $8.689M
YoY Change -15.09% -15.3% -20.04%
Inventory
Prepaid Expenses $9.626M
Receivables $30.00M $30.00M $20.00M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $194.5M $230.0M $185.5M
YoY Change 29.84% 23.99% -8.3%
LONG-TERM ASSETS
Property, Plant & Equipment $43.10M $45.40M $36.37M
YoY Change -18.06% -16.7% -8.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.000M $3.800M $14.30M
YoY Change -18.03% -73.43% 286.49%
Total Long-Term Assets $48.10M $49.20M $98.77M
YoY Change -45.83% -50.2% 5.45%
TOTAL ASSETS
Total Short-Term Assets $194.5M $230.0M $185.5M
Total Long-Term Assets $48.10M $49.20M $98.77M
Total Assets $242.6M $279.2M $284.3M
YoY Change 1.68% -1.79% -3.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.40M $13.80M $9.073M
YoY Change -18.79% 51.65% -30.68%
Accrued Expenses $10.50M $15.70M $5.030M
YoY Change -27.08% -19.07% -8.58%
Deferred Revenue $89.65M
YoY Change -11.19%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.70M $121.0M $118.2M
YoY Change -59.04% 2.37% -9.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $133.3M $67.50M $1.721M
YoY Change 46.48% -28.57% -19.65%
Total Long-Term Liabilities $133.3M $67.50M $94.49M
YoY Change 46.48% -28.57% 11.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.70M $121.0M $118.2M
Total Long-Term Liabilities $133.3M $67.50M $94.49M
Total Liabilities $182.0M $188.6M $212.6M
YoY Change -13.25% -11.29% -0.97%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $539.5M
YoY Change 43.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.82M $90.70M $63.73M
YoY Change
Total Liabilities & Shareholders Equity $242.6M $279.2M $284.3M
YoY Change 1.68% -1.79% -3.93%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$42.46M -$149.9M -$56.77M
YoY Change -10.59% -22.58% 49.84%
Depreciation, Depletion And Amortization $1.948M $8.100M $2.010M
YoY Change -4.46% 6.58% 17.54%
Cash From Operating Activities -$44.38M -$116.0M -$61.24M
YoY Change 69.05% -38.38% 86.59%
INVESTING ACTIVITIES
Capital Expenditures $108.0K $1.338M -$1.350M
YoY Change -81.38% -65.85% -60.98%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$108.0K -$1.338M -$1.350M
YoY Change -81.38% -65.85% -60.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $93.74M
YoY Change -42.06%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.641M 154.5M 760.0K
YoY Change 1307.33% -6.0% 18.75%
NET CHANGE
Cash From Operating Activities -44.38M -116.0M -61.24M
Cash From Investing Activities -108.0K -1.338M -1.350M
Cash From Financing Activities 8.641M 154.5M 760.0K
Net Change In Cash -35.96M 37.34M -61.83M
YoY Change 37.21% -235.11% 73.48%
FREE CASH FLOW
Cash From Operating Activities -$44.38M -$116.0M -$61.24M
Capital Expenditures $108.0K $1.338M -$1.350M
Free Cash Flow -$44.48M -$117.3M -$59.89M
YoY Change 65.8% -38.94% 103.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote for each ordinary share
CY2020Q4 wve Common Stock Votes Per Share
CommonStockVotesPerShare
1
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 wve Common Stock Votes Per Share
CommonStockVotesPerShare
1
CY2020 dei Entity File Number
EntityFileNumber
001-37627
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
U0
CY2020 dei Security12b Title
Security12bTitle
$0 Par Value Ordinary Shares
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q2 dei Entity Public Float
EntityPublicFloat
267103358
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48997368
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184497000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147161000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30000000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
63732000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10434000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
14296000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
741000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20000000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9626000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5111000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8689000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
230042000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
185476000
CY2019Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
30000000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16232000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3651000
CY2020Q4 us-gaap Other Assets
OtherAssets
115000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
49196000
CY2020Q4 us-gaap Assets
Assets
279238000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13795000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11971000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25591000
CY2020 us-gaap Investment Income Dividend
InvestmentIncomeDividend
584000
CY2019 us-gaap Investment Income Dividend
InvestmentIncomeDividend
4912000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-16000
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
29000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2058000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9738000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14679000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-193638000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2607000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
114000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-193638000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93744000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-149910000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
82778000
CY2020 us-gaap Profit Loss
ProfitLoss
-149910000
CY2019 us-gaap Profit Loss
ProfitLoss
-193638000
CY2020 wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
1869000
CY2019 wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
1613000
CY2020 us-gaap Depreciation
Depreciation
8114000
CY2019 us-gaap Depreciation
Depreciation
7588000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14296000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19509000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-20000000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000000
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
808000
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3665000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-14121000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8369000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5117000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3497000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4214000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1448000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-20077000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-15983000
CY2020 wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3243000
CY2019 wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2816000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1247000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-421000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-115982000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-188231000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1338000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3918000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1338000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3918000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93744000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161792000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
741000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2607000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
171000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
154538000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
164399000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37340000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27636000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150808000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178444000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
188148000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
184500000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include the assumptions used to determine the fair value of share-based awards, the Company’s revenue recognition policy, particularly, <span style="Background-color:#FFFFFF;color:#000000;">(a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations</span>, the evaluation of progress to completion of external research and development costs which can result in prepaid or accrued expenses related to the Company’s contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), the valuation allowance required for the Company’s deferred tax assets, determining uncertain tax positions and the related liabilities, and estimating refundable tax credits. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates. </p>
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
188100000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash and cash equivalents, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</p>
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3700000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3600000
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54092000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53371000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24894000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17003000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29198000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36368000
CY2020 us-gaap Depreciation
Depreciation
8100000
CY2019 us-gaap Depreciation
Depreciation
7600000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9003000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8662000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2143000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5030000
CY2020Q4 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
825000
CY2019Q4 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2493000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11971000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16185000
CY2020Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
10
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14296000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19509000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
4472000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
4472000
CY2020 us-gaap Lease Cost
LeaseCost
4472000
CY2019 us-gaap Lease Cost
LeaseCost
4472000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
5846000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
5675000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M24D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
29305000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6021000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6201000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5236000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5002000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5152000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10773000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38385000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9080000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-149910000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-193638000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39227618
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33866487
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.82
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.72
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-150751000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-193638000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-841000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
133841000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
89585000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
36151000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
31336000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5880000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6342000
CY2020Q4 wve Deferred Tax Assets Tax Deferred Expense Accumulated Amortization
DeferredTaxAssetsTaxDeferredExpenseAccumulatedAmortization
962000
CY2019Q4 wve Deferred Tax Assets Tax Deferred Expense Accumulated Amortization
DeferredTaxAssetsTaxDeferredExpenseAccumulatedAmortization
11169000
CY2020Q4 wve Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
8006000
CY2019Q4 wve Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
8892000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
13956000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
14299000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1146000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
424000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
199942000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
162047000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
195381000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
156680000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4561000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
5367000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
4435000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
4945000
CY2020Q4 wve Deferred Tax Liabilities Accumulated Depreciation
DeferredTaxLiabilitiesAccumulatedDepreciation
117000
CY2019Q4 wve Deferred Tax Liabilities Accumulated Depreciation
DeferredTaxLiabilitiesAccumulatedDepreciation
422000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
9000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4561000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
57200000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5367000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
156680000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
99438000
CY2020 wve Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
38653000
CY2019 wve Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
57235000
CY2020 wve Deferred Tax Assets Valuation Foreign Currency Translation
DeferredTaxAssetsValuationForeignCurrencyTranslation
-48000
CY2019 wve Deferred Tax Assets Valuation Foreign Currency Translation
DeferredTaxAssetsValuationForeignCurrencyTranslation
-7000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
195381000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
156680000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
38700000
CY2020 wve Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-310000
CY2019 wve Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-14000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16682000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10219000
CY2020 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
313000
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
23000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2357000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6500000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18416000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16682000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18400000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16700000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
200000
CY2020 wve Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations In Next Twelve Months
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitationsInNextTwelveMonths
200000

Files In Submission

Name View Source Status
0001564590-21-010718-index-headers.html Edgar Link pending
0001564590-21-010718-index.html Edgar Link pending
0001564590-21-010718.txt Edgar Link pending
0001564590-21-010718-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g0yfwugrxy0a000001.jpg Edgar Link pending
g0yfwugrxy0a000002.jpg Edgar Link pending
g2i5pc5dmg5r000001.jpg Edgar Link pending
g2i5pc5dmg5r000002.jpg Edgar Link pending
g2i5pc5dmg5r000003.jpg Edgar Link pending
g2i5pc5dmg5r000004.jpg Edgar Link pending
g2i5pc5dmg5r000005.jpg Edgar Link pending
g2i5pc5dmg5r000006.jpg Edgar Link pending
g2i5pc5dmg5r000007.jpg Edgar Link pending
g2i5pc5dmg5r000008.jpg Edgar Link pending
g2i5pc5dmg5r000009.jpg Edgar Link pending
g2i5pc5dmg5r000010.jpg Edgar Link pending
g2i5pc5dmg5r000011.jpg Edgar Link pending
g2i5pc5dmg5r000012.jpg Edgar Link pending
g2i5pc5dmg5r000013.jpg Edgar Link pending
g2i5pc5dmg5r000014.jpg Edgar Link pending
g2i5pc5dmg5r000015.jpg Edgar Link pending
g2i5pc5dmg5r000016.jpg Edgar Link pending
g2i5pc5dmg5r000017.jpg Edgar Link pending
g2i5pc5dmg5r000018.jpg Edgar Link pending
g2i5pc5dmg5r000019.jpg Edgar Link pending
g2i5pc5dmg5r000020.jpg Edgar Link pending
g2i5pc5dmg5r000021.jpg Edgar Link pending
g2i5pc5dmg5r000022.jpg Edgar Link pending
g2i5pc5dmg5r000023.jpg Edgar Link pending
g2i5pc5dmg5r000024.jpg Edgar Link pending
g2i5pc5dmg5r000025.jpg Edgar Link pending
g2i5pc5dmg5r000026.jpg Edgar Link pending
g2i5pc5dmg5r000027.jpg Edgar Link pending
g2i5pc5dmg5r000028.jpg Edgar Link pending
g2i5pc5dmg5r000029.jpg Edgar Link pending
g2i5pc5dmg5r000030.jpg Edgar Link pending
g2i5pc5dmg5r000031.jpg Edgar Link pending
g2i5pc5dmg5r000032.jpg Edgar Link pending
g2i5pc5dmg5r000033.jpg Edgar Link pending
g2i5pc5dmg5r000034.jpg Edgar Link pending
g2i5pc5dmg5r000035.jpg Edgar Link pending
g2i5pc5dmg5r000036.jpg Edgar Link pending
g2i5pc5dmg5r000037.jpg Edgar Link pending
g2i5pc5dmg5r000038.jpg Edgar Link pending
g2i5pc5dmg5r000039.jpg Edgar Link pending
g2i5pc5dmg5r000040.jpg Edgar Link pending
g2i5pc5dmg5r000041.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wve-10k_20201231.htm Edgar Link pending
wve-10k_20201231_htm.xml Edgar Link completed
wve-20201231.xsd Edgar Link pending
wve-20201231_cal.xml Edgar Link unprocessable
wve-20201231_def.xml Edgar Link unprocessable
wve-20201231_lab.xml Edgar Link unprocessable
wve-20201231_pre.xml Edgar Link unprocessable
wve-ex1015_410.htm Edgar Link pending
wve-ex1052_412.htm Edgar Link pending
wve-ex231_6.htm Edgar Link pending
wve-ex311_9.htm Edgar Link pending
wve-ex312_10.htm Edgar Link pending
wve-ex32_8.htm Edgar Link pending
wve-ex42_411.htm Edgar Link pending